GlassScriptPhysician profile
Kris MD Alden
NPI 1992842132
$1,291,608.29
in general payments reported to CMS, 2019-2025
32 companies · $53K in 2025
The $53K reported for 2025 was more than what 95% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $14K · 2021: $39K · 2022: $15K · 2023: $54K · 2024: $1.1M · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $1.1M · Consulting Fee: $99K · Travel and Lodging: $19K · Food and Beverage: $3,773 · Royalty Or License: $1,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $1,055,607.37 |
| Consulting Fee | $99,283.44 |
| Travel and Lodging | $19,229.55 |
| Food and Beverage | $3,773.18 |
| Royalty Or License | $1,648.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,074,220.65 | 2020-2025 | |
| Medical Device Business Services, INC. | $57,809.72 | 2019-2025 | Actis, Velys, Reclaim |
| Encore Medical, LP | $53,094.09 | 2021-2024 | Djo Surgical |
| Uoc USA INC | $44,141.16 | 2019-2025 | Resolve, U2, Conformity, U-Motion II and Ustar II, Conformity, U-Star II |
| Medwest Associates | $36,141.52 | 2019-2021 | |
| Medacta USA, INC. | $11,722.13 | 2019-2025 | Gmk Sphere, Mpact, Gmk Revision |
| Osteoremedies, LLC | $7,577.50 | 2021 | |
| Depuy Synthes Products, INC. | $4,174.09 | 2021-2022 | |
| Think Surgical, INC. | $630.61 | 2020 | |
| Depuy Synthes Sales INC. | $609.38 | 2019-2025 | Actis, Monovisc |
| Orthalign INC | $351.51 | 2025 | Orthalign Plus |
| Globus Medical, INC. | $277.94 | 2025 | Captivate, Anthem, Arbor |
| Smith+Nephew, INC. | $249.54 | 2019-2025 | |
| Motive Health, INC. | $89.93 | 2019 | |
| Grt US Holding, INC. | $56.00 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $53.94 | 2025 | Durolane |
| Restor3d, INC. | $50.14 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $48.68 | 2020-2024 | Exparel, Iovera, Zilretta |
| Avanos Medical | $42.70 | 2025 | Grpro 2.1 |
| Lima USA, INC. | $38.91 | 2019 | |
| Hydrocision, INC. | $27.08 | 2022 | |
| Merz Pharmaceuticals, LLC | $24.95 | 2023 | Xeomin |
| Collegium Pharmaceutical, INC. | $23.99 | 2023 | Xtampza |
| Pacira Therapeutics, INC. | $23.40 | 2020 | |
| Medtronic, INC. | $22.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.69 | 2021 | |
| Trice Medical, INC. | $19.67 | 2019 | |
| Coastal Medical Technologies LLC | $15.34 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.63 | 2023 | Quviviq |
| Ethicon US, LLC | $13.33 | 2019 | |
| Karl Storz Endoscopy-America | $12.37 | 2019 | |
| Heraeus Medical, LLC. | $9.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kris Alden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.